共 34 条
[1]
CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma
[J].
LEUKEMIA & LYMPHOMA,
2007, 48 (12)
:2424-2436
[4]
HUMAN NEUTROPHIL FC-GAMMA-RECEPTOR DISTRIBUTION AND STRUCTURE
[J].
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES,
1982, 79 (10)
:3275-3279
[6]
Golay J, 2004, HAEMATOLOGICA, V89, P1476
[7]
Hernandez-Ilizaliturri FJ, 2003, CLIN CANCER RES, V9, P5866